SAGE Therapeutics Q4 Loss Widens - Quick Facts

(RTTNews) - SAGE Therapeutics, Inc. (SAGE) reported fourth-quarter net loss attributable to common stockholders of $12.4 million, wider than loss of $5.7 million in the year-ago period.

For fiscal 2014, net loss attributable to common stockholders widened to $36.11 million from $18.29 million in the prior year. However, loss per share narrowed to $1.67 from $12.26 in the previous year.

On average, analysts polled by Thomson Reuters expected the company to report loss of $2.47 per share for the year.

Total operating expenses for the year rose to $33.81 million from $18.28 million last year.